Press release
Acute Myocardial Infarction Market to Evolve with Novel Therapies and Strategic Advancements by 2034 | Forecasts DelveInsight
Acute Myocardial Infarction Market
The "Acute Myocardial Infarction Market Report [https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" by DelveInsight offers a robust analysis of market size, treatment algorithms, and unmet needs across the 7MM, providing stakeholders with actionable insights to navigate a highly competitive and evolving cardiovascular space.
Some of the Key Facts of the Acute Myocardial Infarction Market Report:
- The AMI market in the 7MM is valued at USD 1.6 billion in 2023, with expected strong growth.
- In 2023, the U.S. had ~823K incident AMI cases, projected to rise by 2034.
- LODOCO, FDA-approved by AGEPHA Pharma, is the first treatment targeting residual inflammatory risk in cardiovascular disease.
- NSTEMI cases (~607K) outnumbered STEMI cases in the U.S. in 2023.
- In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the FDA. This recognition highlights PMcardio's innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention.
- In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FLYRCADO (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women.
- Emerging acute myocardial infarction drugs include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
- Leading companies in the acute myocardial infarction market include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.
To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Acute Myocardial Infarction Market Forecast [https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Acute Myocardial Infarction Overview
Acute Myocardial Infarction (AMI) refers to the death of heart muscle tissue due to the sudden blockage of a coronary artery. Common symptoms include chest pain, shortness of breath, nausea, and sweating. Diagnosis is based on electrocardiogram (ECG) findings and cardiac biomarkers. Treatment typically involves antiplatelet and anticoagulant medications, nitrates, beta-blockers, statins, and timely reperfusion therapies. In ST-segment elevation myocardial infarction (STEMI), emergency reperfusion is achieved through fibrinolytics, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). In non-ST-segment elevation myocardial infarction (NSTEMI), PCI or CABG is also used.
AMI remains a leading cause of mortality in developed nations and is classified into two main types: STEMI and NSTEMI. While unstable angina shares similarities with NSTEMI, it does not show elevated cardiac biomarkers.
Get a free sample of the acute myocardial infarction market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market [https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Acute Myocardial Infarction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acute Myocardial Infarction Epidemiology Segmentation:
The Acute Myocardial Infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
- Total Incident Cases of AMI
- Type-Specific Incident Cases of AMI
- Gender-Specific Incident Cases of AMI
Download the report to understand which factors are driving acute myocardial infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast [https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Acute Myocardial Infarction Drugs Uptake, and Pipeline Development Activities
The acute myocardial infarction drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the acute myocardial infarction market or expected to be launched during the study period. The analysis covers the acute myocardial infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the acute myocardial infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Acute Myocardial Infarction Market Strengths
- Strong pipeline with innovative therapies targeting inflammation, thrombosis, and cardiac repair.
- High disease burden and awareness ensure steady demand for treatment and care.
Acute Myocardial Infarction Market Weaknesses
- High treatment costs limit access in low- and middle-income regions.
- Delayed diagnosis and limited emergency care affect outcomes in underserved areas.
Scope of the Acute Myocardial Infarction Market Report
- Study Period: 2020-2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
- Key Acute Myocardial Infarction Companies: Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.
- Acute Myocardial Infarction Therapeutic Assessment: Acute myocardial infarction, currently marketed, and acute myocardial infarction emerging therapies
- Acute Myocardial Infarction Market Dynamics: Acute myocardial infarction market drivers and Acute Myocardial Infarction market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Acute Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Acute Myocardial Infarction Market Access and Reimbursement
To learn more about the key players and advancements in the acute myocardial infarction treatment landscape, visit the Acute Myocardial Infarction Market Analysis Report [https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]
Table of Contents
1. Acute Myocardial Infarction Market Report Introduction
2. Executive Summary for Acute Myocardial Infarction
3. SWOT analysis of Acute Myocardial Infarction
4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance
5. Acute Myocardial Infarction Market Overview at a Glance
6. Acute Myocardial Infarction Disease Background and Overview
7. Acute Myocardial Infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Myocardial Infarction
9. Acute Myocardial Infarction Current Treatment and Medical Practices
10. Acute Myocardial Infarction Unmet Needs
11. Acute Myocardial Infarction Emerging Therapies
12. Acute Myocardial Infarction Market Outlook
13. Country-Wise Acute Myocardial Infarction Market Analysis (2020-2034)
14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies
15. Acute Myocardial Infarction Market Drivers
16. Acute Myocardial Infarction Market Barriers
17. Acute Myocardial Infarction Appendix
18. Acute Myocardial Infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-myocardial-infarction-market-to-evolve-with-novel-therapies-and-strategic-advancements-by-2034-forecasts-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Myocardial Infarction Market to Evolve with Novel Therapies and Strategic Advancements by 2034 | Forecasts DelveInsight here
News-ID: 4020742 • Views: …
More Releases from ABNewswire
Extreme Leadership - A Grit-Filled Journey Through Failure, Resilience, and Succ …
Leadership isn't about titles, prestige, or playing it safe. It's about taking risks, making tough decisions, and pushing forward when the odds seem impossible.
Leadership isn't about titles, prestige, or playing it safe. It's about taking risks, making tough decisions, and pushing forward when the odds seem impossible. Extreme Leadership , the latest book by Dr. Johnny Kula, strips away the cliches and delivers an unfiltered look at what it truly…
European Gold Dealers Report Unprecedented Cross-Border Trading as Americans Cap …
NEW YORK/LONDON - A surge in transatlantic gold trading has emerged as American investors leverage the strong dollar to acquire physical gold from European dealers at historically advantageous exchange rates, according to market data and dealer reports from major European cities including Frankfurt, Zurich, and Cologne.
Dollar Dominance Creates Arbitrage Opportunities in Physical Gold Markets
The U.S. dollar's 15% appreciation against the euro since mid-2024 has created an unusual arbitrage opportunity in…
Motorbike Wreckers Canberra Expands Services to Meet Growing Demand in Australia …
Leading Canberra-based motorcycle dismantling service strengthens position as premier destination for quality used parts and eco-friendly vehicle disposal
FYSHWICK, ACT - August 26, 2025 - As Australia's motor vehicle dismantling and used parts wholesaling industry continues to thrive with a market size of $1.3 billion in 2025, motorcycle wreckers Canberra [http://www.motorcyclewreckerscanberra.com.au/] is positioning itself at the forefront of sustainable automotive recycling practices in the Australian Capital Territory.
The specialized motorcycle dismantling service,…
TazBoostMedia Shatters Industry Norms, Generates $5 Million+ in Revenue for Remo …
In an industry where marketing agencies often overpromise and underdeliver, TazBoostMedia (TBM) has emerged as a game-changer, proving that real partnerships drive real results. Since launching in 2023, the company has helped remodeling and home improvement firms across the U.S. generate over $5 million in additional revenue, establishing itself as one of the fastest-growing agencies in the space.
From Leads to Booked Appointments - A Market Shift
Unlike traditional lead generation companies…
More Releases for Acute
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,…
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…
